Mineralys Therapeutics to Participate in the Guggenheim Securities 6th Annual Biotechnology Conference
January 29 2024 - 4:05PM
Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage
biopharmaceutical company focused on developing medicines to target
hypertension, chronic kidney disease (CKD) and other diseases
driven by abnormally elevated aldosterone, today announced that
Chief Executive Officer Jon Congleton will be participating in a
fireside chat at the Guggenheim Securities 6th Annual Biotechnology
Conference, being held in New York City on February 7-8, 2024.
Guggenheim Securities
6th Annual Biotechnology
Conference: |
Date: |
Thursday, February 8, 2024 |
Time: |
9:00am EST |
Format: |
Fireside Chat |
A live webcast of the fireside chat can be accessed
under “News and Events” on the Investor Relations section of the
Mineralys website at www.mineralystx.com. A replay of the fireside
chat will be available on the Company’s website for approximately
90 days.
About Mineralys
TherapeuticsMineralys Therapeutics is a clinical-stage
biopharmaceutical company focused on developing medicines to target
hypertension, CKD and other diseases driven by abnormally elevated
aldosterone. Its initial product candidate, lorundrostat, is a
proprietary, orally administered, highly selective aldosterone
synthase inhibitor that Mineralys Therapeutics is developing for
cardiorenal conditions affected by abnormally elevated aldosterone,
including hypertension and CKD. Mineralys is based in Radnor,
Pennsylvania, and was founded by Catalys Pacific. For more
information, please visit https://mineralystx.com. Follow Mineralys
on LinkedIn and Twitter.
Contact:
Investor
Relationsinvestorrelations@mineralystx.com
Media RelationsTom WeibleElixir
Health Public RelationsPhone: (1) 515-707-9678Email:
tweible@elixirhealthpr.com
Mineralys Therapeutics (NASDAQ:MLYS)
Historical Stock Chart
From Jul 2024 to Aug 2024
Mineralys Therapeutics (NASDAQ:MLYS)
Historical Stock Chart
From Aug 2023 to Aug 2024